NasdaqGS:DVAXBiotechs
Assessing Dynavax Technologies (DVAX) Valuation After Recent Share Price Momentum And Ongoing Pipeline Investment
Key snapshot of Dynavax Technologies
Dynavax Technologies (DVAX) has drawn investor attention recently as its shares trade around $15.49, with returns roughly flat over the past month and a gain over the past 3 months.
The commercial stage vaccine maker reports annual revenue of about US$330.514 million and a net loss of roughly US$43.401 million, giving investors a mix of established product sales and ongoing investment in its pipeline.
See our latest analysis for Dynavax Technologies.
While...